AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Tamoxifen and soluble tumor-associated antigens suppress breast cancer.
2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Treatment with tamoxifen and soluble tumor-associated antigens stimulate T- and B-lymphocyte responses to breast cancer tumors.
According to recent research published in the journal Oncology Reports, "We analyzed the role of T- and B-lymphocytes in the antitumor effects of the anticancer drug tamoxifen and soluble tumor-associated antigens (sTAA) on rat mammary carcinogenesis. Studies were performed on the spleen from the following groups of mammary tumor-bearing rats. Rats in group 1 were not exposed to DMBA and served as age-related controls."
"Rats in other groups were exposed to DMBA and received different types of treatment: rats in group 2 received no additional treatment and served as carcinogen-related controls; rats in group 3 were treated with the commercial hormone-dependent anticancer drug tamoxifen by weekly subcutaneous (s.c.) injections of 10 mg dissolved in 0.5 mL distilled water per rat; rats in group 4 were vaccinated s.c. weekly with a preparation of sTAA (50 microliter/rat) dissolved in 0.5 mL of phosphate-buffered saline; rats in group 5 were treated with tamoxifen and were also vaccinated with a preparation of sTAA," reported H. Benhur and colleagues at Hebrew University of Jerusalem.
"Different zones of the spleen were measured and their T- and B-cell contents were analyzed immunohistochemically," stated the researchers. "The treatment with tamoxifen significantly increased the total number of lymphocytes in the follicles, PALS (periarterial lymph sheath), and red pulp relative to all other groups. The combined treatment with tamoxifen and sTAA increased the areas of white pulp, the ...
- Identification, Characterization, and Clinical Applications of Tumor-Associated...
- Press release article from: M2 Presswire April 9, 2009 700+ words
...Clinical Applications of Tumor-Associated Antigens(C)1994-2009 M2 COMMUNICATIONS...Sons Ltd's new report "Tumor-Associated Antigens: Identification, Characterization...Key Topics Covered: TUMOUR-ASSOCIATED ANTIGENS (TAAS): SUBCLASSES OF TAAS...
- Pathway for cell-associated antigens by dendritic cells characterized.
- Newspaper article from: Biotech Business Week February 9, 2004 700+ words
...presentation pathway for cell-associated antigens by human dendritic cells. According...dendritic cells (DCs) of cell-associated antigens derived from physiologically relevant...presentation pathway for cell-associated antigens by human dendritic cells. Blood...
- Tumor-associated antigens show promise for prostate cancer vaccines.
- Newspaper article from: Vaccine Weekly July 7, 2004 700+ words
...net) -- Scientists have identified potential tumor-associated antigens for the development of prostate cancer vaccines. According...research from Norway, "Serological cloning of tumor-associated antigens (TAAs) using patient autoantibodies and tumor cDNA expression...
- Two novel tumor-associated antigens recognized by T lymphocytes identified.
- Newspaper article from: Drug Week January 30, 2004 700+ words
...net) -- Researchers have identified two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes...Molecular Medicine (Identification of two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes...
- IMS HEALTH Launches New Oncology Reports Tracking Cancer Treatment Trends in...
- Press release article from: Business Wire November 27, 2000 700+ words
...RX) today announced the launch of Oncology Reports, a comprehensive pharmaceutical information...pharmaceutical and healthcare industries. "Oncology Reports helps users to identify emerging cancer...major oncology treatment centers, Oncology Reports provides baseline data on ...
- The Drug Target Atlas Of Apoptopic Drugs In Oncology Reports On 90 Unique Drug...
- Press release article from: M2 Presswire February 13, 2008 700+ words
M2 PRESSWIRE-13 February 2008-Research and Markets: The Drug Target Atlas Of Apoptopic Drugs In Oncology Reports On 90 Unique Drug Target Combinations(C)1994-2008 M2 COMMUNICATIONS LTD RDATE:13022008 Dublin - Research and Markets...
- ZIOPHARM ONCOLOGY REPORTS DISPOSITION BY CEO LEWIS (New York)
- News wire article from: US Fed News Service, Including US State News December 8, 2009 700+ words
WASHINGTON, Dec. 8 -- Ziopharm Oncology Inc. (ZIOP), New York, has filed a Form 4 with the Securities and Exchange Commission noting the change in the beneficial interest held by CEO and Director Jonathan Lewis, New York. On Dec. 3 the action involved disposition of 47,625 shares of stock. Lewis
- US Oncology Reports Financial Results for Second Quarter 2003; Quarter produces...
- Press release article from: PR Newswire August 7, 2003 700+ words
US Oncology, Inc. today reported results for the second quarter ended June 30, 2003. US Oncology recorded year-over-year increases in net operating revenue, net income and earnings per share for the second quarter of 2003. The following table provides a review of the quarter's results, along with
Source: HighBeam Research, Tamoxifen and soluble tumor-associated antigens suppress breast...